Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A - 24/04/13
Correspondence to: Nelly Rubeiz, MD, Department of Dermatology, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh St, Beirut, Lebanon.Abstract |
Background |
Pachydermoperiostosis (PDP) is a rare hereditary disorder characterized by digital clubbing, periostosis, and pachydermia. Pachydermia results in leonine facies, a major cause of cosmetic and functional morbidity in these patients. Its treatment is usually surgical. So far, no medical treatment has been suggested to alleviate this morbidity.
Objective |
We sought to assess the role of botulinum toxin type A (BTX-A) in improving the cosmetic appearance of pachydermia in patients with PDP.
Methods |
Three patients with PDP were treated with BTX-A for their leonine facies. A total of 70 to 80 U were used to treat the upper third of the face. Photographs were taken at baseline and at 2 and 6 weeks after the injections. The patients were followed up periodically for at least 6 months. Wrinkle severity was assessed at relaxation using the 4-point facial wrinkle scale at baseline, week 6, and month 6. In addition, a subjective assessment of the improvement of the extent and depth of the facial rhytides/furrows over the upper third of the face was performed by the same investigator at week 6 and month 6.
Results |
Using the subjective assessment of the improvement of wrinkles, all 3 patients exhibited a fair to excellent response at week 6 that started manifesting 1 week after the BTX-A treatment. All patients demonstrated a residual effect 6 months after the treatment. One patient exhibited a mild exacerbation of his ptosis.
Limitations |
Major limitations were the small number of patients and the administration of BTX-A injections and assessment of their response by a single unblinded physician.
Conclusion |
BTX-A is a simple procedure that may be of value in temporarily improving the cosmetic appearance of pachydermia in patients with PDP.
Le texte complet de cet article est disponible en PDF.Key words : botulinum toxin type A, leonine facies, pachydermia, pachydermoperiostosis, primary hypertropic osteoarthropathy
Abbreviations used : BTX-A, FWS, PDP, PGE2
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 63 - N° 6
P. 1036-1041 - décembre 2010 Retour au numéro
Article précédent
- A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women
- Sreedevi Kodali, Ian L. Guevara, Christina R. Carrigan, Seema Daulat, Gabriela Blanco, Andreas Boker, Linda S. Hynan, Amit G. Pandya
- Gummy smile and botulinum toxin: A new approach based on the gingival exposure area
- Rosemarie Mazzuco, Dóris Hexsel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?